Highlights Signed an agreement with a U.S.-based prescription telehealth and infrastructure partner to support compliant prescribing, fulfillment, and delivery of the Company’s peptide products Builds on the Company’s recently announced 503A compounding agreement, under which all peptides -including BPC-157- are to be 100% compounded in the United States Partner platform is trusted by more than 100 telehealth brands and is designed to align with U.S. legal, HIPAA, and pharmacy regulations Connects licensed provider networks across all 50 U.S. states with prescription and pharmacy fulfillment workflows Supports a compliant, nationwide U.S. infrastructure for prescription-based peptide access ahead of anticipated U.S. regulatory developments
Vancouver, British Columbia–(Newsfile Corp. – June 9, 2026) – The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the “Company” or “BPC”), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has signed an agreement with a U.S.-based prescription telehealth and infrastructure partner (the “Partner”) to support compliant prescribing, fulfillment, and delivery of the Company’s peptide products. This news follows the Company’s recently announced compounding agreement with a U.S.-based 503A sterile compounding pharmacy, under which all of the Company’s peptides – including BPC-157 – are to be 100% compounded in the United States (see news release dated June 2, 2026).
This excerpt is quoted from the original release. Read the full announcement on Newsfile Corp.
Brief Summary
The Precision Peptide Company has taken a significant step to enhance its U.S. operations by establishing a partnership with a prescription telehealth provider. This deal is critical for ensuring compliant access to peptide products nationwide.
- Compliant Prescribing: Agreement supports safe and legal prescribing.
- National Reach: The partner connects over 100 telehealth brands across all 50 states.
- Regulatory Alignment: Infrastructure complies with U.S. legal, HIPAA, and pharmacy regulations.
- Local Compounding: Peptides, including BPC-157, will be compounded in the U.S.
Why it matters: This strategic move positions BPC to capitalize on upcoming regulatory changes, ensuring swift access to peptide therapies for patients nationwide.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.